CSIMarket
 


Quidel Corporation  (QDEL)
Other Ticker:  
 
 

QDEL's Free Cash Flow Growth by Quarter and Year

Quidel's Free Cash Flow results by quarter and year




QDEL Free Cash Flow (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 439.13 47.72 43.22
III Quarter September - 70.46 13.33 6.67
II Quarter June -178.02 59.00 40.53 50.65
I Quarter March 585.46 61.18 32.90 35.81
FY   407.44 629.77 134.48 136.35



QDEL Free Cash Flow second quarter 2021 Y/Y Growth Comment
Quidel Corporation in the second quarter recorded free cash outflow of $ -178.02 millions.

Looking into second quarter results within In Vitro & In Vivo Diagnostic Substances industry 18 other companies have achieved higher Free Cash Flow growth. While Quidel Corporation' s Free Cash Flow no change of % ranks overall at the positon no. 1777 in the second quarter.




QDEL Free Cash Flow ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 820.22 % 10.41 % 32.9 %
III Quarter September - 428.58 % 99.85 % -
II Quarter June - 45.57 % -19.98 % -
I Quarter March 856.95 % 85.96 % -8.13 % 21.06 %
FY   - 368.3 % -1.37 % 391.88 %

Financial Statements
Quidel's second quarter 2021 Free Cash Flow $ -178.02 millions QDEL's Income Statement
Quidel's second quarter 2020 Free Cash Flow $ 59.00 millions Quarterly QDEL's Income Statement
New: More QDEL's historic Free Cash Flow Growth >>


QDEL Free Cash Flow (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 523.23 % 257.99 % 547.98 %
III Quarter September - 19.42 % -67.11 % -86.83 %
II Quarter June - -3.56 % 23.19 % 41.44 %
I Quarter March 33.32 % 28.21 % -23.88 % 10.12 %
FY (Year on Year)   - 368.3 % -1.37 % 391.88 %




Free Cash Flow second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #19
Healthcare Sector #148
Overall #1777

Free Cash Flow Y/Y Growth Statistics
High Average Low
146.15 % 23.36 % -75.01 %
(Mar 31 2017)   (March 31, 2016)
Free Cash Flow second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #19
Healthcare Sector #148
Overall #1777
Free Cash Flow Y/Y Growth Statistics
High Average Low
146.15 % 23.36 % -75.01 %
(Mar 31 2017)   (March 31, 2016)

Free Cash Flow by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Quidel's Q/Q Free Cash Flow Growth


Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


QDEL's II. Quarter Q/Q Free Cash Flow Comment
II. Quarter 2021 results of -178.02 millions by Quidel Corporation look even worse compare to the free cash outflow 585.46 millions in the first quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Quidel Corporation achieved highest sequential Free Cash Flow growth. While Quidel's Free Cash Flow growth quarter on quarter, overall rank is .


Free Cash Flow Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


QDEL's II. Quarter Q/Q Free Cash Flow Comment
Recent accomplishment of -178.02 millions by Quidel Corporation appear even more unfavourable considering the 585.46 millions free cash outflow in the previous quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Quidel Corporation achieved highest sequential Free Cash Flow growth. While Quidel's Free Cash Flow growth quarter on quarter, overall rank is .


Quidel's 12 Months Free Cash Flow Growth Year on Year


Free Cash Flow TTM Growth

12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
Cumulative Free Cash Flow 12 Months Ending $ 1,122.09 $ 1,291.37 $ 694.69 $ 282.98 $ 210.06
Y / Y Free Cash Flow Growth (TTM) 434.17 % 576.51 % 329.58 % 79.66 % 37.11 %
Year on Year Free Cash Flow Growth Overall Ranking # 60 # 57 # 61 # 235 # 194
Seqeuential Free Cash Flow Change (TTM) -13.11 % 85.89 % 145.49 % 34.71 % 10.05 %
Seq. Free Cash Flow Growth (TTM) Overall Ranking # 2125 # 120 # 53 # 420 # 266




Cumulative Free Cash Flow growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual Free Cash Flow surge of 434.17% year on year, of $ 1,122 millions.
This marks a slow-down of the companys growth trends and from the 576.51% surge in Mar 31 2021.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Free Cash Flow growth total ranking has deteriorated compare to previous quarter from 57 to 60.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
146.15 %
23.36 %
-75.01 %
 

Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 9
Overall # 60

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
576.51 %
111.95 %
-76.31 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 178
S&P 500 # 2125
Cumulative Free Cash Flow growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual Free Cash Flow surge of 434.17% year on year, of $ 1,122 millions.
This marks a slow-down of the companys growth trends and from the 576.51% surge in Mar 31 2021.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Free Cash Flow growth total ranking has deteriorated compare to previous quarter from 57 to 60.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
146.15 %
23.36 %
-75.01 %
 


Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 9
Overall # 60

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
576.51 %
111.95 %
-76.31 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 178
S&P 500 # 2125




Other Free Cash Flow Growth
In Vitro & In Vivo Diagnostic Substances Industry Free Cash Flow Growth Trends and Statistics
Healthcare Sector Free Cash Flow Growth Statistics
Free Cash Flow Growth Trends for overall market
QDEL's Free Cash Flow Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Free Cash Flow Growth
Lowest Ranking Free Cash Flow Growth
Free Cash Flow Growth for QDEL's Competitors
Free Cash Flow Growth for Quidel's Suppliers
Free Cash Flow Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar Free Cash Flow surge for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Free Cash Flow for the quarter ending Jun 30 2021
Apollo Medical Holdings Inc -2.44%$ -2.442 millions
West Pharmaceutical Services Inc -2.50%$ -2.498 millions
Cumberland Pharmaceuticals Inc -4.13%$ -4.131 millions
Mustang Bio inc -5.00%$ -5.004 millions
Elanco Animal Health Inc-6.47%$ -6.466 millions
Merit Medical Systems Inc-7.09%$ -7.089 millions
Prestige Consumer Healthcare Inc -7.78%$ -7.783 millions
Semler Scientific inc -7.86%$ -7.863 millions
Fonar Corporation-8.08%$ -8.079 millions
United Therapeutics Corporation-9.63%$ -9.634 millions
Gilead Sciences Inc -9.74%$ -9.743 millions
Horizon Therapeutics Public Limited Company-10.24%$ -10.240 millions
Lifevantage Corp-10.43%$ -10.429 millions
Capital Senior Living Corporation-13.08%$ -13.084 millions
Neurocrine Biosciences Inc -13.20%$ -13.204 millions
Ligand Pharmaceuticals Incorporated-16.43%$ -16.426 millions
Corcept Therapeutics Inc-16.63%$ -16.634 millions
Hill rom Holdings Inc -16.70%$ -16.698 millions
Teva Pharmaceutical Industries Ltd-20.15%$ -20.147 millions
Vanda Pharmaceuticals Inc -20.78%$ -20.782 millions
Phibro Animal Health Corp-20.82%$ -20.815 millions
Novocure Limited-22.18%$ -22.181 millions
Catalent Inc -22.24%$ -22.235 millions
Immucell Corp-24.59%$ -24.595 millions
Steris Plc-27.36%$ -27.360 millions
Regional Health Properties Inc -27.45%$ -27.451 millions
Bristol Myers Squibb Co-28.32%$ -28.320 millions
Eli Lilly And Company-28.85%$ -28.849 millions
Insulet Corporation-30.68%$ -30.682 millions
Resmed Inc -31.41%$ -31.411 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

APTM's Profile

Stock Price

APTM's Financials

Business Description

Fundamentals

Charts & Quotes

APTM's News

Suppliers

APTM's Competitors

Customers & Markets

Economic Indicators

APTM's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071